Drugs · acquisition-cost intelligence
oxcarbazepine
· ingredient oxcarbazepine· OXCARBAZEPINE 300 mg/5mL; OXCARBAZEPINE 60 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.12615
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 8 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other oxcarbazepine products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| oxcarbazepine | $0.16663 | +$0.04050 |
| Oxcarbazepine | $0.24219 | +$0.11600 |
| OXTELLAR XR | $7.10 | +$6.97 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 4
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.